Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O43390
UPID:
HNRPR_HUMAN
Alternative names:
-
Alternative UPACC:
O43390; Q2L7G6; Q5TEH1; Q9BV64; S4R3J4
Background:
Heterogeneous nuclear ribonucleoprotein R (hnRNP R) plays a pivotal role in the processing of precursor mRNA in the nucleus, as a component of ribonucleosomes. These complexes, comprising at least 20 different hnRNP proteins, are crucial for the post-transcriptional regulation of gene expression.
Therapeutic significance:
The protein is linked to a neurodevelopmental disorder characterized by developmental delays, structural brain abnormalities, and skeletal defects. Understanding the role of Heterogeneous nuclear ribonucleoprotein R could open doors to potential therapeutic strategies for this disorder.